Crescent Biopharma, Inc.
CBIOAs of the close on Sep 25, 2026
Price
$13.99
Market cap
$520M
P/E (diluted TTM)
—
Per-share earnings are not available for each of the last four quarters
EPS (TTM)
—
Per-share earnings are not available for each of the last four quarters
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Crescent Biopharma, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 14 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 23, 2026. The latest institutional report shown is dated Mar 31, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| BARCLAYS PLC | 2025-03-31 | 76 | Not shown | SEC filing |
| Truvestments Capital LLC | 2025-03-31 | 1,309 | Not shown | SEC filing |
| STATE STREET CORP | 2025-03-31 | 179,265 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2025-03-31 | 30,580 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2025-03-31 | 126 | Not shown | SEC filing |
| Virtu Financial LLC | 2025-03-31 | 36,326 | Not shown | SEC filing |
| VR ADVISER, LLC | 2025-03-31 | 3,000,000 | Not shown | SEC filing |
| Royal Bank of Canada | 2025-03-31 | 2,000 | Not shown | SEC filing |
| BlackRock, Inc. | 2025-03-31 | 726,300 | Not shown | SEC filing |
| HRT FINANCIAL LP | 2025-03-31 | 10,032 | Not shown | SEC filing |
| TWO SIGMA SECURITIES, LLC | 2025-03-31 | 15,740 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-03-31 | 5,176 | Not shown | SEC filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2025-03-31 | 5,091,231 | Not shown | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2025-03-31 | 787 | Not shown | SEC filing |
| WELLINGTON MANAGEMENT GROUP LLP | 2025-03-31 | 1,370,297 | Not shown | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2025-03-31 | 571,726 | Not shown | SEC filing |
| GROUP ONE TRADING LLC | 2025-03-31 | 24,425 | Not shown | SEC filing |
| IEQ CAPITAL, LLC | 2025-03-31 | 38,363 | Not shown | SEC filing |
| Tower Research Capital LLC (TRC) | 2025-03-31 | 9,353 | Not shown | SEC filing |
| Logos Global Management LP | 2025-03-31 | 5,400,000 | Not shown | SEC filing |
- Each value is checked against Crescent Biopharma, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Vanguard Personalized Indexing Management, LLC: 26,304 shares reported 2024-12-31; 16,936 shares reported 2025-03-31.
- CONCOURSE FINANCIAL GROUP SECURITIES, INC.: 0 shares reported 2024-12-31; 0 shares reported 2025-03-31.
- Pine Valley Investments Ltd Liability Co: 12,520 shares reported 2024-12-31; 12,520 shares reported 2025-03-31.
- MILLENNIUM MANAGEMENT LLC: 14,419 shares reported 2024-12-31; 13,854 shares reported 2025-03-31.
- NORTHERN TRUST CORP: 116,985 shares reported 2024-12-31; 116,985 shares reported 2025-03-31.
- BNP PARIBAS FINANCIAL MARKETS: 481 shares reported 2024-12-31; 481 shares reported 2025-03-31.
- Intellectus Partners, LLC: 45,965 shares reported 2024-12-31; 45,965 shares reported 2025-03-31.
- BVF INC/IL: 9,544,262 shares reported 2024-12-31; 9,544,262 shares reported 2025-03-31.
- Jefferies Financial Group Inc.: 423,777 shares reported 2024-12-31; 585,000 shares reported 2025-03-31.
- SBI Securities Co., Ltd.: 6,942 shares reported 2024-12-31; 6,942 shares reported 2025-03-31.
- UBS Group AG: 228,868 shares reported 2024-12-31; 465,913 shares reported 2025-03-31.
- 1 NORTH WEALTH SERVICES LLC: 12,000 shares reported 2024-12-31; 12,000 shares reported 2025-03-31.
Showing the 12 most recent filer reports.
19 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Crescent Biopharma, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-07-30 · DEBBANE RAYMOND: Larger than 31 of the 33 other insider sales of Common Stock on file. SEC filing
- 2024-07-29 · DEBBANE RAYMOND: Larger than 30 of the 33 other insider sales of Common Stock on file. SEC filing
- 2023-02-16 · Artal Group S.A.: Larger than 25 of the 26 other insider purchases of Common Stock on file. SEC filing
- 2023-02-15 · Artal Group S.A.: Larger than all 26 other insider purchases of Common Stock on file. SEC filing
- 2023-01-26 · SANDELL SCOTT D: Larger than 32 of the 33 other insider sales of Common Stock on file. SEC filing
- 2023-01-26 · SANDELL SCOTT D: Larger than all 33 other insider sales of Common Stock on file. SEC filing
- 2019-09-05 · BVF PARTNERS L P/IL: Larger than all 8 other insider purchases of Common Stock, $0.001 par value on file. SEC filing
Independent insiders buying near the same time
- 2024-06-18–2024-06-21: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2023-05-08–2023-05-10: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2022-11-11–2022-11-17: 8 event(s) across 7 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-22 | Scalzo Richard William · Chief Financial Officer | Ordinary Shares | S — Open market or private sale | −1,112 | 17.99 | SEC filing |
| 2026-06-22 | Pinkas Jan · Chief Scientific Officer | Ordinary Shares | S — Open market or private sale | −1,288 | 17.99 | SEC filing |
| 2026-06-22 | McNeill Jonathan · President and COO | Ordinary Shares | S — Open market or private sale | −20,549 | 17.99 | SEC filing |
| 2026-06-22 | Brumm Joshua T · Chief Executive Officer | Ordinary Shares | S — Open market or private sale | −42,305 | 17.99 | SEC filing |
| 2026-06-22 | Lynch Ryan · See Remarks | Ordinary Shares | S — Open market or private sale | −465 | 17.99 | SEC filing |
| 2026-06-22 | Im Ellie Eunkyung · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −1,219 | 17.99 | SEC filing |
| 2026-06-22 | Bispham Barbara Harlin · See Remarks | Ordinary Shares | S — Open market or private sale | −1,218 | 17.99 | SEC filing |
| 2025-12-04 | Harwin Peter Evan · Director, 10% owner | Pre-Funded Warrant (Right to Buy) | P — Open market or private purchase | +131,434 | 13.41 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-02 | Violin Jonathan · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +11,050 | SEC filing |
| 2026-06-02 | Harwin Peter Evan · Director, 10% owner | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +11,050 | SEC filing |
| 2026-06-02 | Moran Susan · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +11,050 | SEC filing |
| 2026-06-02 | Balcom Alexandra · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +11,050 | SEC filing |
| 2026-06-02 | Lubner David Charles · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +11,050 | SEC filing |
| 2025-12-15 | Bispham Barbara Harlin · See Remarks | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +72,185 | SEC filing |
| 2025-12-15 | Scalzo Richard William · Chief Financial Officer | Ordinary Shares | A — Grant, award, or other acquisition | +14,422 | SEC filing |
| 2025-12-15 | McNeill Jonathan · President and COO | Ordinary Shares | A — Grant, award, or other acquisition | +6,000 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-06-13 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Pre-Funded Warrants to Purchase Common Stock | J — Other acquisition or disposition | +304,098 | SEC filing |
| 2025-06-13 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Common Stock | J — Other acquisition or disposition | +657,308 | SEC filing |
| 2025-06-13 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Pre-Funded Warrants to Purchase Common Stock | J — Other acquisition or disposition | +25,944 | SEC filing |
| 2025-06-13 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Common Stock | J — Other acquisition or disposition | +56,079 | SEC filing |
| 2025-06-13 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Pre-Funded Warrants to Purchase Common Stock | J — Other acquisition or disposition | +257,515 | SEC filing |
| 2025-06-13 | BIOTECHNOLOGY VALUE FUND L P · 10% owner | Common Stock | J — Other acquisition or disposition | +556,617 | SEC filing |
| 2022-08-02 | King Rachel K. · Director | Common Stock | W — Acquisition or disposition by will or laws of descent | +7,500 | SEC filing |
| 2022-02-15 | King Rachel K. · Director | Common Stock | W — Acquisition or disposition by will or laws of descent | +11,641 | SEC filing |
Showing 8 of 8 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.